Growing Leadership The recent appointment of a new Chief Executive Officer in August 2022 indicates strategic leadership changes that could open avenues for collaborative projects or new initiative funding within the organization.

Recognition & Credibility Receiving the Sustained Excellence Award from the Indiana Cancer Consortium in April 2021 enhances the company's reputation, making it a more attractive partner for pharmaceutical and biotech companies looking for reputable research collaborators.

Research Focus Specializing in early phase multi-center oncology clinical trials across a broad nationwide network positions Hoosier Cancer Research Network as a key player for organizations seeking clinical trial management and investigator-initiated studies.

Technology Adoption Utilizing a diverse tech stack including secure data management, SEO, analytics, and internet security tools demonstrates operational maturity, which can be leveraged to assure potential partners of robust, compliant research environments.

Funding & Revenue With revenues estimated at up to $10 million, the company shows steady growth potential, presenting opportunities for negotiations around research grants, collaboration funding, or partnership investments in expanding oncology trials and research initiatives.